Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.

Yu AP, Atanasov P, Ben-Hamadi R, Birnbaum H, Stensland MD, Philips G.

Value Health. 2009 Jul-Aug;12(5):708-15. doi: 10.1111/j.1524-4733.2008.00498.x.

2.

Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.

Yu AP, Ben-Hamadi R, Birnbaum HG, Atanasov P, Stensland MD, Philips G.

Curr Med Res Opin. 2009 Mar;25(3):755-64. doi: 10.1185/03007990802683579 .

PMID:
19199435
3.

Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.

Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.

Curr Med Res Opin. 2004 Dec;20(12):1883-93.

PMID:
15701206
4.

Cost of antipsychotic polypharmacy in the treatment of schizophrenia.

Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.

BMC Psychiatry. 2008 Apr 4;8:19. doi: 10.1186/1471-244X-8-19.

5.

Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.

Jing Y, Kim E, You M, Pikalov A, Tran QV.

J Med Econ. 2009 Jun;12(2):104-13. doi: 10.3111/13696990903044092.

PMID:
19527195
6.
7.

Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.

Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P.

J Med Assoc Thai. 2005 Sep;88(9):1267-77.

PMID:
16536115
8.

Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.

Jing Y, Johnston SS, Fowler R, Bates JA, Forbes RA, Hebden T.

J Med Econ. 2011;14(6):777-86. doi: 10.3111/13696998.2011.625066. Epub 2011 Sep 29.

PMID:
21954966
9.

The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.

Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.

Value Health. 2004 Jan-Feb;7(1):22-35.

10.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
11.
12.

Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.

Law WL, Hui HY, Young WM, You JH.

Int J Clin Pharmacol Ther. 2007 May;45(5):264-70.

PMID:
17542348
13.

Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.

Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL.

Pharmacoeconomics. 2003;21(10):683-97.

PMID:
12828491
14.

Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.

Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P.

Value Health. 2009 Nov-Dec;12 Suppl 3:S66-9. doi: 10.1111/j.1524-4733.2009.00630.x.

15.

The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.

Chen L, McCombs JS, Park J.

Value Health. 2008 Jan-Feb;11(1):34-43. doi: 10.1111/j.1524-4733.2007.00212.x.

16.

A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.

Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, Riemsma R.

Health Technol Assess. 2004 May;8(19):iii-iv, 1-187. Review.

17.

Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.

Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.

J Manag Care Pharm. 2012 Nov-Dec;18(9):676-89.

18.

Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder.

Zhu B, Kulkarni PM, Stensland MD, Ascher-Svanum H.

Curr Med Res Opin. 2007 Nov;23(11):2805-14.

PMID:
17910804
19.

Cost analysis in a Medicaid program for patients with bipolar disorder who initiated atypical antipsychotic monotherapy.

Qiu Y, Christensen DB, Fu AZ, Liu GG.

Curr Med Res Opin. 2009 Feb;25(2):351-61. doi: 10.1185/03007990802634077 .

PMID:
19192979
20.

Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.

Kopala L, Smith G, Malla A, Williams R, Love L, Talling D, Balshaw R.

Acta Psychiatr Scand Suppl. 2006;(430):29-39.

PMID:
16542323

Supplemental Content

Support Center